The American Cancer Society on Thursday issued its first major revision to prostate cancer screening guidance since 2010, now urging routine PSA blood testing rather than leaving the decision to individual men and their doctors.

Under the new guideline, men at average risk should get a PSA test every two years from age 50 through 69. For higher-risk groups — Black men and men with a strong family history of prostate cancer — annual screening is recommended starting at 45. After 70, the decision becomes individualized, and screening should stop after 80 or for men not expected to live another 10 years.

The shift reverses years of caution. Once a favored biomarker, routine PSA screening fell out of favor and was dropped from the guidelines in 2010 because it is not specific enough: many men underwent follow-up procedures despite having no cancer, or only slow-growing tumors.

To curb overdiagnosis, the new guideline sets the threshold for an elevated PSA at 3.0 ng/mL or higher — rather than the 4.0 many labs still report as normal — calls for two elevated readings before further action, and recommends an MRI and/or other biomarkers before a biopsy. It also stresses active surveillance for slow-growing cancers.

The U.S. Preventive Services Task Force, whose recommendations determine what insurers must cover, still advises against population-wide PSA screening and has not updated its guidance; it says an update is coming.